Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: A case report

被引:3
作者
Kinoshita, Tatsuya [1 ]
Inoue, Hitoshi [1 ]
Kinouchi, Toshiro [1 ]
Kobayashi, Masao [1 ]
Takada, Tsuyoshi [1 ]
Hara, Tsuneo [1 ]
Hatano, Koji [2 ]
Nonomura, Norio [2 ]
机构
[1] Ikeda Municipal Hosp, Dept Urol, Ikeda, Osaka 5638510, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
关键词
multi-kinase inhibitor; preoperative; renal cancer; sorafenib; TARGETED THERAPY;
D O I
10.1111/j.1442-2042.2009.02444.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib. Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes. With a short period of sorafenib administration, marked shrinkage of the renal mass and lymphadenopathy was observed after the patient experienced fulminant hepatic failure and a severe hand-foot skin reaction. Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively. Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy. Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma. The lymph nodes that were resected were negative for malignancy. At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
引用
收藏
页码:286 / 288
页数:3
相关论文
共 50 条
  • [21] Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
    Zimmermann, Kaja
    Schmittel, Alexander
    Steiner, Ursula
    Asemissen, Anne Marie
    Knoedler, Maren
    Thiel, Eckhard
    Miller, Kurt
    Keilholz, Ulrich
    ONCOLOGY, 2009, 76 (05) : 350 - 354
  • [22] A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
    J M G Larkin
    T R Ferguson
    L M Pickering
    K Edmonds
    M G James
    K Thomas
    U Banerji
    B Berns
    C de Boer
    M E Gore
    British Journal of Cancer, 2010, 103 : 1149 - 1153
  • [23] A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
    Larkin, J. M. G.
    Ferguson, T. R.
    Pickering, L. M.
    Edmonds, K.
    James, M. G.
    Thomas, K.
    Banerji, U.
    Berns, B.
    de Boer, C.
    Gore, M. E.
    BRITISH JOURNAL OF CANCER, 2010, 103 (08) : 1149 - 1153
  • [24] Hyperkalemia in a Patient with Advanced Hepatocellular Carcinoma Probably Due to Sorafenib: Case Report
    Uyeturk, Ummugul
    Budakoglu, Burcin
    Helvaci, Kaan
    Sonmez, Ozlem Uysal
    Turker, Ibrahim
    Arslan, Ulku Yalcintas
    Oksuzoglu, Berna
    Zengin, Nurullah
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2012, 32 (02): : 585 - 587
  • [25] Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series
    Montella, Liliana
    Addeo, Raffaele
    Cennamo, Gregorio
    Vincenzi, Bruno
    Palmieri, Rita
    Sperlongano, Pasquale
    Sperlongano, Rossella
    Iodice, Patrizia
    Russo, Paola
    Del Prete, Salvatore
    ONCOLOGY, 2013, 84 (05) : 265 - 272
  • [26] Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report
    Pinter, Matthias
    Sieghart, Wolfgang
    Reisegger, Michael
    Wrba, Friedrich
    Peck-Radosavljevic, Markus
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (1-2) : 61 - 64
  • [27] Sorafenib in der Therapie des fortgeschrittenen NierenzellkarzinomsSorafenib in the treatment of advanced renal cell carcinoma
    C. Doehn
    H.-D. Peters
    Der Onkologe, 2006, 12 (10): : 1043 - 1053
  • [28] Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma
    Francesca Valcamonico
    Vittorio Ferrari
    Vito Amoroso
    Giovanni Rangoni
    Edda Simoncini
    Patrizia Marpicati
    Lucia Vassalli
    Salvatore Grisanti
    Giovanni Marini
    Journal of Neuro-Oncology, 2009, 91 : 47 - 50
  • [29] Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
    Molina, Ana M.
    Hutson, Thomas E.
    Nosov, Dmitry
    Tomczak, Piotr
    Lipatov, Oleg
    Sternberg, Cora N.
    Motzer, Robert
    Eisen, Tim
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 87 - 94
  • [30] Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
    Negrier, S.
    Jaeger, E.
    Porta, C.
    McDermott, D.
    Moore, M.
    Bellmunt, J.
    Anderson, S.
    Cihon, F.
    Lewis, J.
    Escudier, B.
    Bukowski, R.
    MEDICAL ONCOLOGY, 2010, 27 (03) : 899 - 906